Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Dietary Salt in Postural Tachycardia Syndrome

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2013 by Vanderbilt University
Sponsor:
Information provided by (Responsible Party):
Satish R. Raj, Vanderbilt University
ClinicalTrials.gov Identifier:
NCT01547117
First received: March 2, 2012
Last updated: January 7, 2013
Last verified: January 2013

March 2, 2012
January 7, 2013
March 2012
March 2017   (final data collection date for primary outcome measure)
blood volume [ Time Frame: after 7 days of each dietary sodium level ] [ Designated as safety issue: No ]
DAXOR (131-I labelled albumin) blood volume assay
Same as current
Complete list of historical versions of study NCT01547117 on ClinicalTrials.gov Archive Site
Magnitude of suppression of aldosterone (from low sodium to high sodium diets) and a reduction in orthostatic tachycardia and orthostatic symptoms in POTS patients with the high-sodium diet. [ Time Frame: after 7 days of each dietary sodium intervention ] [ Designated as safety issue: No ]
Whether plasma renin activity and aldosterone are modified appropriately by changes in dietary sodium in POTS & whether patients with POTS have improvements in their orthostatic tachycardia and symptoms as a result of a high dietary sodium level.
Same as current
Not Provided
Not Provided
 
Dietary Salt in Postural Tachycardia Syndrome
Dietary Salt in Postural Tachycardia Syndrome

Patients with POTS may not adequately expand their plasma volume in response to a high-sodium diet. Mechanisms involved in the regulation of plasma volume, such as the renin-angiotensin-aldosterone system and renal DA, may be impaired in POTS and may respond inappropriately to changes in dietary sodium.The purpose of this study is to determine (1) whether a high dietary sodium level appropriately expands plasma volume in POTS; (2) whether plasma renin activity and aldosterone are modified appropriately by changes in dietary sodium in POTS; and (3) whether patients with POTS have improvements in their orthostatic tachycardia and symptoms as a result of a high dietary sodium level.

Study Day 1

  • Start 150 mEq Na+/day diet (POTS patients as inpatients; healthy control subjects with CRC provided outpatient diet)
  • Start a 24h urine collection (for Na+, K+, Cr, fractionated catecholamines)
  • Blood work
  • Blood volume - carbon monoxide rebreathing

Study Day 2

  • Complete 24h urine
  • Start STUDY DIET (10 mEq Na+/day or 300 mEq Na+/day in a random order) after 3 meals of 150 mEq Na+/day are complete; water ad lib

Study Day 3 - 5

  • Continue STUDY DIET; water ad lib
  • On Day 5, a 24 hr holter combined ECG monitor will be placed on the subjects.

Study Day 6

  • Continue STUDY DIET; water ad lib
  • Remove 24h Holter combined ECG monitor and BP monitor from subject
  • Start a 24h urine collection (for Na+, K+, Cr, fractionated catecholamines)
  • Complete questionnaires
  • NPO after midnight for study next day

Study Day 7 (BIG DAY)

  • Awaken early (~6am) to void (still collecting 24h urine)
  • Patient returns to bed, IV catheter inserted
  • Posture Study (in morning; between 7-8am ideally)
  • Blood pressure and heart rate will be measured while supine and then while standing for up to 30 minutes
  • We will draw 3 tablespoons of blood in each body position to measure hormones that regulate blood pressure and blood volume
  • Hormones to verify the subject's phase of menstrual cycle
  • Serum/plasma aliquots for future analysis
  • Subjects will rate symptoms during supine period and at end of stand using Vanderbilt Orthostatic Symptoms Score (VOSS)
  • Total Blood Volume (DAXOR)- using injection of iodinated I-131 tagged human serum albumin nominally 25 micro-Ci of radiation blood samples drawn through IV catheter before injection and for ~30 minutes post-injection (total - 25 ml)
  • This will be done after supine assessment, but before standing the subject up
  • Autonomic Function Test with Cardiac Output and Brief Tilt
  • The subject will be tilted up to 60-75 degrees head-up tilt for up to 10 minutes to measure the changes in heart rate and blood pressure and symptoms with upright challenge.
  • Blood volume - carbon monoxide rebreathing
  • Exercise Capacity Test (in the afternoon) Will estimate maximal oxygen consumption (VO2 max) This test will be conducted on a stationary bicycle. Effort will be gradually increase while expired air is measured during exhaustive physical work.

All procedures are repeated at least a month later with the 2nd level of dietary salt. (Randomized to high or low salt to the first phase, the second phase is the remaining level)

Interventional
Not Provided
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Basic Science
Postural Orthostatic Tachycardia Syndrome
  • Radiation: Blood Volume
    we will measure the amount of hemoglobin and myoglobin in the body by a procedure called carbon monoxide (CO) rebreathing. One teaspoon of blood is taken before and after a small amount of CO has been absorbed into the bloodstream.
    Other Name: CO-RBC Blood Volume
  • Radiation: Total Blood Volume
    Using injection of iodinated I-131 tagged human serum albumin nominally 25 micro-Ci of radiation, blood samples are drawn before and 30 minutes after injection.
    Other Name: DAXOR
  • Procedure: Exercise Capacity Test - Bicycle
    subjects breath room air through a mouthpiece and exhale the air into a tube that connects to a machine (metabolic cart) that analyzes carbon dioxide and oxygen content, which allows the investigator to calculate the amount of oxygen they are using under resting and exercise conditions.
    Other Name: VO2 Max (maximal oxygen consumption)
  • Procedure: Posture Study
    Blood pressure and heart rate will be measured while supine and then while standing for up to 30 minutes. Blood will be drawn in each position to measure hormones that regulate blood pressure and blood volume.
    Other Name: Standing Orthostatic Challenge
  • Experimental: High Sodium Level
    POTS and healthy controls will be randomly assigned the order of dietary sodium levels. All procedures are performed at both levels.
    Interventions:
    • Radiation: Blood Volume
    • Radiation: Total Blood Volume
    • Procedure: Exercise Capacity Test - Bicycle
    • Procedure: Posture Study
  • Experimental: Low Sodium Dietary Level
    Interventions:
    • Radiation: Blood Volume
    • Radiation: Total Blood Volume
    • Procedure: Exercise Capacity Test - Bicycle
    • Procedure: Posture Study
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
30
March 2017
March 2017   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosed with postural tachycardia syndrome by the Vanderbilt Autonomic Dysfunction Center
  • Increase in heart rate ≥30 beats/min with position change from supine to standing (10 minutes)
  • Chronic symptoms consistent with POTS that are worse when upright and get better with recumbence
  • Age between 18-50 years old
  • Non-smokers
  • Premenopausal patients with POTS and healthy volunteers
  • Only female participants are eligible.
  • Since 80-90% of POTS patients are female, and there can be differences in measures with the menstrual cycle, including a small number of males might introduce a significant amount of noise.
  • Able and willing to provide informed consent

Exclusion Criteria:

  • Smokers
  • Overt cause for postural tachycardia, i.e., acute dehydration
  • Significant cardiovascular, pulmonary, hepatic, or hematological disease by history or screening results
  • Pregnant (positive pregnancy test) or breastfeeding
  • Hypertension defined as supine resting BP>145/95 mmHg off medications or needing antihypertensive medication
  • Other factors which in the investigator's opinion would prevent the participant from completing the protocol, including poor compliance during previous studies or an unpredictable schedule
  • Unable to give informed consent
Both
18 Years to 50 Years
Yes
Contact: Satish Raj, MD, MSCI 615-322-2931 adcresearch@vanderbilt.edu
Contact: Victor Nwazue, MD 615-322-2931 adcresearch@vanderbilt.edu
United States
 
NCT01547117
111261
No
Satish R. Raj, Vanderbilt University
Vanderbilt University
Not Provided
Principal Investigator: Satish R Raj, MD MSCI Vanderbilt University
Vanderbilt University
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP